Nanobodies: A Promising Toolkit for Diagnostic Applications

Abstract

Nanobodies are single-domain antigen-binding fragments derived from camelid heavy-chain-only antibodies (HCAbs). They combine a small size (~12–15 kDa) with high solubility, favorable stability, and antigen-binding capability. These properties can facilitate recognition of less accessible epitopes, improve tissue penetration in selected settings, and support assay performance under conditions that may challenge conventional antibodies. In recent years, nanobodies have emerged as versatile molecular recognition tools for diagnostic applications and been integrated into diverse detection platforms—including enzyme-linked immunosorbent assay (ELISA), lateral flow immunoassays (LFIAs), biosensors, and in vivo imaging techniques such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and nanobody–quantum dot conjugates. Advances such as multivalent designs, site-specific conjugation, and optimized expression systems have further enhanced the performance of nanobodies in clinical diagnostics. Here, we summarize recent progress in nanobody-based diagnostic technologies, outlining the key structural and biochemical features that contribute to their efficacy, reviewing ongoing clinical trials, and highlighting successful technological developments. Additionally, we discuss emerging strategies aimed at creating scalable, sensitive, and application-ready nanobody-enabled diagnostic platforms.

Keywords

biosensors / diagnostic applications / immunoassays / molecular imaging / nanobodies

References

[1] A. C. Chan, G. D. Martyn, and P. J. Carter, “Fifty Years of Monoclonals: The Past, Present and Future of Antibody Therapeutics,” Nature Reviews Immunology 25, no. 10 (2025): 745–765.

[2] P. J. Gardner, C. Loynachan, T. L. Tsekoa, L. Keir, V. Yabannavar, and E. Sparrow, “Manufacturing Innovation Is Essential for Monoclonal Antibody Affordability and Access,” Nature Reviews Bioengineering 3, no. 6 (2025): 438–440.

[3] L. Roy, P. Buragohain, and V. Borse, “Strategies for Sensitivity Enhancement of Point-of-Care Devices,” Biosensors and Bioelectronics: X 10 (2022): 100098.

[4] Y. Liu, L. Zhan, Z. Qin, J. Sackrison, and J. C. Bischof, “Ultrasensitive and Highly Specific Lateral Flow Assays for Point-of-Care Diagnosis,” ACS Nano 15, no. 3 (2021): 3593–3611.

[5] S. Gao, J. M. Guisán, and J. Rocha-Martin, “Oriented Immobilization of Antibodies Onto Sensing Platforms—A Critical Review,” Analytica Chimica Acta 1189 (2022): 338907.

[6] N. G. Welch, J. A. Scoble, B. W. Muir, and P. J. Pigram, “Orientation and Characterization of Immobilized Antibodies for Improved Immunoassays (Review),” Biointerphases 12, no. 2 (2017): 02D301.

[7] Y. Zhang, X. Kuang, J. Yi, et al., “Revolutionizing the Capture Efficiency of Ultrasensitive Digital Elisa via an Antibody Oriented-Immobilization Strategy,” Journal of Materials Chemistry B 12, no. 39 (2024): 10041–10053.

[8] Z. Karbalaee, A. H. Rezayan, R. A. Taheri, S. A. Mirhosseini, and M. Barshan-Tashnizi, “Enhancing Shiga Toxin Detection Using Surface Plasmon Resonance a Study of Antibody Immobilization Strategies,” Scientific Reports 15, no. 1 (2025): 17024.

[9] C. Rodriguez, S. Delaney, S. M. Sarrett, O. M. Keinänen, and B. M. Zeglis, “Antibody Engineering for Nuclear Imaging and Radioimmunotherapy,” Journal of Nuclear Medicine 63, no. 9 (2022): 1316–1322.

[10] A. Krasniqi, M. D'Huyvetter, N. Devoogdt, et al., “Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology,” Journal of Nuclear Medicine 59, no. 6 (2018): 885–891.

[11] A. T. Mayer and S. S. Gambhir, “The Immunoimaging Toolbox,” Journal of Nuclear Medicine 59, no. 8 (2018): 1174–1182.

[12] S. J. Walsh, J. D. Bargh, F. M. Dannheim, et al., “Site-Selective Modification Strategies in Antibody-Drug Conjugates,” Chemical Society Reviews 50, no. 2 (2021): 1305–1353.

[13] H. Ma, C. Ó'Fágáin, and R. O'Kennedy, “Antibody Stability: A Key to Performance—Analysis, Influences and Improvement,” Biochimie 177 (2020): 213–225.

[14] A. Gray, A. R. M. Bradbury, A. Knappik, A. Plückthun, C. A. K. Borrebaeck, and S. Dübel, “Animal-Free Alternatives and the Antibody Iceberg,” Nature Biotechnology 38, no. 11 (2020): 1234–1239.

[15] V. Marx, “Calling the Next Generation of Affinity Reagents,” Nature Methods 10, no. 9 (2013): 829–833.

[16] M. I. Ahmad, C. G. Amorim, L. F. Abu Qatouseh, and M. C. B. S. M. Montenegro, “Nanobody-Based Immunodiagnostics: A Systematic Review of Nanobody Integration in Diagnostics and Deep Insight Into Electrochemical Immunoassays,” Microchemical Journal 196 (2024): 109628.

[17] Z. Eftekhari and F. Kazemi-Lomedasht, “Nanobody-Based Imaging: Advancing Precision in Molecular Diagnostics,” Biochimica et Biophysica Acta (BBA)—General Subjects 1870, no. 1 (2026): 130884.

[18] E. Alexander and K. W. Leong, “Discovery of Nanobodies: A Comprehensive Review of Their Applications and Potential Over the Past Five Years,” Journal of Nanobiotechnology 22, no. 1 (2024): 661.

[19] C. Qi, R. Guo, Y. Chen, et al., “(68)Ga-NC-BCH Whole-Body PET Imaging Rapidly Targets Claudin18.2 in Lesions in Gastrointestinal Cancer Patients,” Journal of Nuclear Medicine 65, no. 6 (2024): 856–863.

[20] J. S. Bloch, S. Mukherjee, J. Kowal, et al., “Development of a Universal Nanobody-Binding Fab Module for Fiducial-Assisted Cryo-EM Studies of Membrane Proteins,” Proceedings of the National Academy of Sciences of the United States of America 118, no. 47 (2021): e2115435118.

[21] C. Hamers-Casterman, T. Atarhouch, S. Muyldermans, et al., “Naturally Occurring Antibodies Devoid of Light Chains,” Nature 363, no. 6428 (1993): 446–448.

[22] S. Muyldermans, “Nanobodies: Natural Single-Domain Antibodies,” Annual Review of Biochemistry 82, no. 1 (2013): 775–797.

[23] H. Revets, P. De Baetselier, and S. Muyldermans, “Nanobodies as Novel Agents for Cancer Therapy,” Expert Opinion on Biological Therapy 5, no. 1 (2005): 111–124.

[24] L. P. Daley, L. F. Gagliardo, M. S. Duffy, M. C. Smith, and J. A. Appleton, “Application of Monoclonal Antibodies in Functional and Comparative Investigations of Heavy-Chain Immunoglobulins in New World Camelids,” Clinical and Diagnostic Laboratory Immunology 12, no. 3 (2005): 380–386.

[25] D. R. Maass, J. Sepulveda, A. Pernthaner, and C. B. Shoemaker, “Alpaca (Lama pacos) as a Convenient Source of Recombinant Camelid Heavy Chain Antibodies (VHHs),” Journal of Immunological Methods 324, no. 1–2 (2007): 13–25.

[26] M. Seligmann, E. Mihaesco, J. L. Preud'homme, F. Danon, and J. C. Brouet, “Heavy Chain Diseases: Current Findings and Concepts,” Immunological Reviews 48 (1979): 145–167.

[27] S. Muyldermans, T. Atarhouch, J. Saldanha, J. A. R. G. Barbosa, and R. Hamers, “Sequence and Structure of VH Domain From Naturally Occurring Camel Heavy Chain Immunoglobulins Lacking Light Chains,” Protein Engineering, Design and Selection 7, no. 9 (1994): 1129–1135.

[28] B. Jin, S. Odongo, M. Radwanska, and S. Magez, “Nanobodies: A Review of Diagnostic and Therapeutic Applications,” International Journal of Molecular Sciences 24, no. 6 (2023): 5994.

[29] M. Sun, Z. Ning, Z. Tu, Y. Li, and Q. He, “Advances of Nanobody-Based Immunoassay Platforms: Promising Diagnosis Tools,” Journal of Analysis and Testing 10 (2026): 164–186.

[30] S. Spinelli, L. Frenken, D. Bourgeois, et al., “The Crystal Structure of a Llama Heavy Chain Variable Domain,” Nature Structural & Molecular Biology 3, no. 9 (1996): 752–757.

[31] L. S. Mitchell and L. J. Colwell, “Analysis of Nanobody Paratopes Reveals Greater Diversity Than Classical Antibodies,” Protein Engineering, Design and Selection 31, no. 7–8 (2018): 267–275.

[32] K. Conrath, C. Vincke, B. Stijlemans, et al., “Antigen Binding and Solubility Effects Upon the Veneering of a Camel VHH in Framework-2 to Mimic a VH,” Journal of Molecular Biology 350, no. 1 (2005): 112–125.

[33] S. Kinoshita, M. Nakakido, C. Mori, D. Kuroda, J. M. M. Caaveiro, and K. Tsumoto, “Molecular Basis for Thermal Stability and Affinity in a VHH: Contribution of the Framework Region and Its Influence in the Conformation of the CDR3,” Protein Science 31, no. 11 (2022): e4450.

[34] K. M. Chow, S. W. Whiteheart, J. R. Smiley, et al., “Immunization of Alpacas (Lama pacos) With Protein Antigens and Production of Antigen-Specific Single Domain Antibodies,” Journal of Visualized Experiments 10, no. 143 (2019): e58471.

[35] M. Wang, L. Wei, H. Xiang, et al., “A Megadiverse Naïve Library Derived From Numerous Camelids for Efficient and Rapid Development of VHH Antibodies,” Analytical Biochemistry 657 (2022): 114871.

[36] J. Yan, G. Li, Y. Hu, W. Ou, and Y. Wan, “Construction of a Synthetic Phage-Displayed Nanobody Library With CDR3 Regions Randomized by Trinucleotide Cassettes for Diagnostic Applications,” Journal of Translational Medicine 12 (2014): 343.

[37] Y. Ding, Z. Tan, J. Li, et al., “Artificial Intelligence for Organelle Segmentation in Live-Cell Imaging,” Research 8 (2025): 1035.

[38] F. Khodabakhsh, M. Behdani, A. Rami, and F. Kazemi-Lomedasht, “Single-Domain Antibodies or Nanobodies: A Class of Next-Generation Antibodies,” International Reviews of Immunology 37, no. 6 (2018): 316–322.

[39] M. Arbabi Ghahroudi, A. Desmyter, L. Wyns, R. Hamers, and S. Muyldermans, “Selection and Identification of Single Domain Antibody Fragments From Camel Heavy-Chain Antibodies,” FEBS Letters 414, no. 3 (1997): 521–526.

[40] A. Desmyter, K. Decanniere, S. Muyldermans, and L. Wyns, “Antigen Specificity and High Affinity Binding Provided by One Single Loop of a Camel Single-Domain Antibody,” Journal of Biological Chemistry 276, no. 28 (2001): 26285–26290.

[41] Q. Li, W. Wang, H. Yin, K. Zou, Y. Jiao, and Y. Zhang, “One-Dimensional Implantable Sensors for Accurately Monitoring Physiological and Biochemical Signals,” Research 7 (2024): 0507.

[42] U. Zavrtanik, J. Lukan, R. Loris, J. Lah, and S. Hadži, “Structural Basis of Epitope Recognition by Heavy-Chain Camelid Antibodies,” Journal of Molecular Biology 430, no. 21 (2018): 4369–4386.

[43] Z. Bahrami Dizicheh, I. L. Chen, and P. Koenig, “VHH CDR-H3 Conformation Is Determined by VH Germline Usage,” Communications Biology 6, no. 1 (2023): 864.

[44] V. K. Nguyen, R. Hamers, L. Wyns, and S. Muyldermans, “Camel Heavy-Chain Antibodies: Diverse Germline V(H)H and Specific Mechanisms Enlarge the Antigen-Binding Repertoire,” EMBO Journal 19, no. 5 (2000): 921–930.

[45] J. Govaert, M. Pellis, N. Deschacht, et al., “Dual Beneficial Effect of Interloop Disulfide Bond for Single Domain Antibody Fragments,” Journal of Biological Chemistry 287, no. 3 (2012): 1970–1979.

[46] Z. Zhuang, Z. Feng, J. Wang, et al., “Advanced Imaging for Live-Cell Spatiotemporal Monitoring: Technologies and Applications,” Research 9 (2026): 1085.

[47] W. G. Lesniak, C. Chu, A. Jablonska, et al., “PET Imaging of Distinct Brain Uptake of a Nanobody and Similarly-Sized PAMAM Dendrimers After Intra-Arterial Administration,” European Journal of Nuclear Medicine and Molecular Imaging 46, no. 9 (2019): 1940–1951.

[48] Y. Wouters, T. Jaspers, B. De Strooper, and M. Dewilde, “Identification and In Vivo Characterization of a Brain-Penetrating Nanobody,” Fluids and Barriers of the CNS 17, no. 1 (2020): 62.

[49] J. R. Haynes, C. A. Whitmore, W. J. Behof, et al., “Targeting Soluble Amyloid-Beta Oligomers With a Novel Nanobody,” Scientific Reports 14, no. 1 (2024): 16086.

[50] E. Ruiz-López and A. J. Schuhmacher, “Transportation of Single-Domain Antibodies Through the Blood–Brain Barrier,” Biomolecules 11, no. 8 (2021): 1131.

[51] E. Dolk, C. van Vliet, J. M. J. Perez, et al., “Induced Refolding of a Temperature Denatured Llama Heavy-Chain Antibody Fragment by Its Antigen,” Proteins 59, no. 3 (2005): 555–564.

[52] P. Kunz, K. Zinner, N. Mücke, T. Bartoschik, S. Muyldermans, and J. D. Hoheisel, “The Structural Basis of Nanobody Unfolding Reversibility and Thermoresistance,” Scientific Reports 8, no. 1 (2018): 7934.

[53] C. J. Bond, J. Marsters, and S. S. Sidhu, “Contributions of CDR3 to VHH Domain Stability and the Design of Monobody Scaffolds for Naive Antibody Libraries,” Journal of Molecular Biology 332, no. 3 (2003): 643–655.

[54] P. Kunz, T. Flock, N. Soler, et al., “Exploiting Sequence and Stability Information for Directing Nanobody Stability Engineering,” Biochimica et Biophysica Acta (BBA)—General Subjects 1861, no. 9 (2017): 2196–2205.

[55] A. Gómez-Mulas, M. Cano-Muñoz, E. Salido Ruiz, and A. L. Pey, “Thermodynamic Versus Kinetic Basis for the High Conformational Stability of Nanobodies for Therapeutic Applications,” FEBS Letters 599, no. 5 (2025): 766–776.

[56] G. Hussack, T. Hirama, W. Ding, R. MacKenzie, and J. Tanha, “Engineered Single-Domain Antibodies With High Protease Resistance and Thermal Stability,” PLoS One 6, no. 11 (2011): e28218.

[57] Y. Wu, “Trends in Nanobody Technology in Industrialization,” Discover Nano 20, no. 1 (2025): 23.

[58] P. Debie, N. Devoogdt, and S. Hernot, “Targeted Nanobody-Based Molecular Tracers for Nuclear Imaging and Image-Guided Surgery,” Antibodies 8, no. 1 (2019): 12.

[59] T. S. Pillay and S. Muyldermans, “Application of Single-Domain Antibodies (‘Nanobodies’) to Laboratory Diagnosis,” Annals of Laboratory Medicine 41, no. 6 (2021): 549–558.

[60] J. Liu, L. Wu, A. Xie, et al., “Unveiling the New Chapter in Nanobody Engineering: Advances in Traditional Construction and AI-Driven Optimization,” Journal of Nanobiotechnology 23, no. 1 (2025): 87.

[61] J.-P. Salvador, L. Vilaplana, and M.-P. Marco, “Nanobody: Outstanding Features for Diagnostic and Therapeutic Applications,” Analytical and Bioanalytical Chemistry 411, no. 9 (2019): 1703–1713.

[62] I. Vaneycken, J. Govaert, C. Vincke, et al., “In Vitro Analysis and In Vivo Tumor Targeting of a Humanized, Grafted Nanobody in Mice Using Pinhole SPECT/Micro-CT,” Journal of Nuclear Medicine 51, no. 7 (2010): 1099–1106.

[63] Y. Wang, Y. Wang, G. Chen, Y. Li, W. Xu, and S. Gong, “Quantum-Dot-Based Theranostic Micelles Conjugated With an Anti-EGFR Nanobody for Triple-Negative Breast Cancer Therapy,” ACS Applied Materials & Interfaces 9, no. 36 (2017): 30297–30305.

[64] P. Bannas, L. Well, A. Lenz, et al., “In Vivo Near-Infrared Fluorescence Targeting of T Cells: Comparison of Nanobodies and Conventional Monoclonal Antibodies,” Contrast Media & Molecular Imaging 9, no. 2 (2014): 135–142.

[65] D. I. Frecot, S. Blaess, T. R. Wagner, et al., “Making the Effect Visible—OX40 Targeting Nanobodies for In Vivo Imaging of Activated T Cells,” Frontiers in Immunology 15 (2024): 1480091.

[66] P. Bannas, A. Lenz, V. Kunick, et al., “Molecular Imaging of Tumors With Nanobodies and Antibodies: Timing and Dosage Are Crucial Factors for Improved In Vivo Detection,” Contrast Media & Molecular Imaging 10, no. 5 (2015): 367–378.

[67] K. De Groeve, N. Deschacht, C. De Koninck, et al., “Nanobodies as Tools for In Vivo Imaging of Specific Immune Cell Types,” Journal of Nuclear Medicine 51, no. 5 (2010): 782–789.

[68] E. Y. Yang and K. Shah, “Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics,” Frontiers in Oncology 10 (2020): 1182.

[69] M. Lemaire, M. D'Huyvetter, T. Lahoutte, et al., “Imaging and Radioimmunotherapy of Multiple Myeloma With Anti-Idiotypic Nanobodies,” Leukemia 28, no. 2 (2014): 444–447.

[70] S. Muyldermans, “Applications of Nanobodies,” Annual Review of Animal Biosciences 9, no. 1 (2021): 401–421.

[71] S. Muyldermans, “A Guide To: Generation and Design of Nanobodies,” FEBS Journal 288, no. 7 (2021): 2084–2102.

[72] M. S. Valdés-Tresanco, A. Molina-Zapata, A. G. Pose, and E. Moreno, “Structural Insights Into the Design of Synthetic Nanobody Libraries,” Molecules 27, no. 7 (2022): 2198.

[73] B. Liu and D. Yang, “Easily Established and Multifunctional Synthetic Nanobody Libraries as Research Tools,” International Journal of Molecular Sciences 23, no. 3 (2022): 1482.

[74] L. Wang, J. Dong, C. Wu, et al., “Development of a Synthetic Library of Humanized Nanobodies for Targeted IL-6 Inhibition,” Frontiers in Bioengineering and Biotechnology 12 (2024): 1440150.

[75] E. Pardon, T. Laeremans, S. Triest, et al., “A General Protocol for the Generation of Nanobodies for Structural Biology,” Nature Protocols 9, no. 3 (2014): 674–693.

[76] M. M. Harmsen, F. Harders, S. van de Water, et al., “Optimization of Blood Sampling Time for Isolation of Antigen Binding Single-Domain Antibodies From Immunized Llamas,” Journal of Immunological Methods 539 (2025): 113844.

[77] X. Peyrassol, T. Laeremans, M. Gouwy, et al., “Development by Genetic Immunization of Monovalent Antibodies (Nanobodies) Behaving as Antagonists of the Human ChemR23 Receptor,” Journal of Immunology 196, no. 6 (2016): 2893–2901.

[78] C. G. C. Vincke, U. Wernery, N. Devoogdt, G. Hassanzadeh-Ghassabeh, and S. Muyldermans, “Generation of Single Domain Antibody Fragments Derived From Camelids and Generation of Manifold Constructs,” Methods in Molecular Biology 907 (2012): 145–176.

[79] J. Qiu, J. Li, Z. Zhang, et al., “Construction of an Alpaca Immune Antibody Library for the Selection of Nanobodies Against Drosophila Melanogaster Proteins,” Frontiers in Bioengineering and Biotechnology 11 (2023): 1207048.

[80] T. Eden, S. Menzel, J. Wesolowski, et al., “A cDNA Immunization Strategy to Generate Nanobodies Against Membrane Proteins in Native Conformation,” Frontiers in Immunology 8 (2018): 1989.

[81] R. Janssens, S. Dekker, R. W. Hendriks, et al., “Generation of Heavy-Chain-Only Antibodies in Mice,” Proceedings of the National Academy of Sciences of the United States of America 103, no. 41 (2006): 15130–15135.

[82] D. Drabek, R. Janssens, E. de Boer, et al., “Expression Cloning and Production of Human Heavy-Chain-Only Antibodies From Murine Transgenic Plasma Cells,” Frontiers in Immunology 7 (2016): 619.

[83] V. K. Nguyen, X. Zou, M. Lauwereys, L. Brys, M. Brüggemann, and S. Muyldermans, “Heavy-Chain Only Antibodies Derived From Dromedary Are Secreted and Displayed by Mouse B Cells,” Immunology 109, no. 1 (2003): 93–101.

[84] T. Eden, A. Z. Schaffrath, J. Wesolowski, et al., “Generation of Nanobodies From Transgenic ‘Lamamice’ Lacking an Endogenous Immunoglobulin Repertoire,” Nature Communications 15, no. 1 (2024): 4728.

[85] S. C. Clarke, B. Ma, N. D. Trinklein, et al., “Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies,” Frontiers in Immunology 9 (2019): 3037.

[86] B. Ma, M. J. Osborn, S. Avis, et al., “Human Antibody Expression in Transgenic Rats: Comparison of Chimeric IgH Loci With Human V_H, D and J_H but Bearing Different Rat C-Gene Regions,” Journal of Immunological Methods 400–401 (2013): 78–86.

[87] J. Yan, P. Wang, M. Zhu, et al., “Characterization and Applications of Nanobodies Against Human Procalcitonin Selected From a Novel Naïve Nanobody Phage Display Library,” Journal of Nanobiotechnology 13 (2015): 33.

[88] A. Olichon and A. de Marco, “Preparation of a Naïve Library of Camelid Single Domain Antibodies,” Methods in Molecular Biology 911 (2012): 65–78.

[89] H. E. Lee, A. H. Cho, J. H. Hwang, et al., “Development, High-Throughput Profiling, and Biopanning of a Large Phage Display Single-Domain Antibody Library,” International Journal of Molecular Sciences 25, no. 9 (2024): 4791.

[90] X. Chen, M. Gentili, N. Hacohen, and A. Regev, “A Cell-Free Nanobody Engineering Platform Rapidly Generates SARS-CoV-2 Neutralizing Nanobodies,” Nature Communications 12, no. 1 (2021): 5506.

[91] C. Zahnd, P. Amstutz, and A. Plückthun, “Ribosome Display: Selecting and Evolving Proteins In Vitro That Specifically Bind to a Target,” Nature Methods 4, no. 3 (2007): 269–279.

[92] K. Y. F. Yau, G. Dubuc, S. Li, et al., “Affinity Maturation of a V(H)H by Mutational Hotspot Randomization,” Journal of Immunological Methods 297, no. 1–2 (2005): 213–224.

[93] L. Yi, X. Guo, Y. Liu, Jirimutu, and Z. Wang, “Single-Cell 5′ RNA Sequencing of Camelid Peripheral B Cells Provides Insights Into Cellular Basis of Heavy-Chain Antibody Production,” Computational and Structural Biotechnology Journal 23 (2024): 1705–1714.

[94] Q. Su, W. Shi, X. Huang, S. Yin, X. Yang, and X. Lu, “Recent Advances of Nanobody Applications in Diagnosis and Detection,” MedComm—Biomaterials and Applications 2, no. 3 (2023): e54.

[95] I. Zimmermann, P. Egloff, C. A. Hutter, et al., “Synthetic Single Domain Antibodies for the Conformational Trapping of Membrane Proteins,” eLife 7 (2018): e34317.

[96] C. McMahon, A. S. Baier, R. Pascolutti, et al., “Yeast Surface Display Platform for Rapid Discovery of Conformationally Selective Nanobodies,” Nature Structural & Molecular Biology 25, no. 3 (2018): 289–296.

[97] E. Moreno, M. S. Valdés-Tresanco, A. Molina-Zapata, and O. Sánchez-Ramos, “Structure-Based Design and Construction of a Synthetic Phage Display Nanobody Library,” BMC Research Notes 15, no. 1 (2022): 124.

[98] M. Nakakido, S. Kinoshita, and K. Tsumoto, “Development of Novel Humanized VHH Synthetic Libraries Based on Physicochemical Analyses,” Scientific Reports 14, no. 1 (2024): 19533.

[99] M. M. Harmsen and H. J. De Haard, “Properties, Production, and Applications of Camelid Single-Domain Antibody Fragments,” Applied Microbiology and Biotechnology 77, no. 1 (2007): 13–22.

[100] S. Sun, Z. Ding, X. Yang, et al., “Nanobody: A Small Antibody With Big Implications for Tumor Therapeutic Strategy,” International Journal of Nanomedicine 16 (2021): 2337–2356.

[101] L. G. J. Frenken, R. H. J. Van Der Linden, P. W. J. J. Hermans, et al., “Isolation of Antigen Specific Llama VHH Antibody Fragments and Their High Level Secretion by Saccharomyces Cerevisiae,” Journal of Biotechnology 78, no. 1 (2000): 11–21.

[102] W. Chen, J. Yang, Q. Niu, et al., “A Phage-Displayed Nanobody-Based Competitive Immunoassay for the Detection of African Swine Fever Virus Antibodies,” Virology Journal 22, no. 1 (2025): 182.

[103] G. Alon-Zchut, R. Zalk, T. T. Huynh, et al., “Structural Analysis of Nanobody Interactions With Their Prostate-Specific Membrane Antigen Binding Epitopes,” International Journal of Biological Macromolecules 320, no. Pt 1 (2025): 145693.

[104] A. Santos, A. P. Macedo de Souza Brandão, B. M. Hryniewicz, et al., “COVID-19 Impedimetric Biosensor Based on Polypyrrole Nanotubes, Nickel Hydroxide and VHH Antibody Fragment: Specific, Sensitive, and Rapid Viral Detection in Saliva Samples,” Materials Today Chemistry 30 (2023): 101597.

[105] M. F. Pavan, C. M. Malnero, M. E. Mora Alvarado, et al., “Engineered Nanobodies for Early and Accurate Diagnosis of Dengue Virus Infection,” PLoS Neglected Tropical Diseases 19, no. 10 (2025): e0013168.

[106] J.-P. Ayrton, C. Ho, H. Zhang, V. Chudasama, S. Frank, and M. R. Thomas, “Multivalent Nanobody Engineering for Enhanced Physisorption and Functional Display on Gold Nanoparticles,” Nanoscale 16, no. 42 (2024): 19881–19896.

[107] S. M. Anbuhl, X. Dervillez, S. Neubacher, et al., “Multivalent CXCR4-Targeting Nanobody Formats Differently Affect Affinity, Receptor Clustering, and Antagonism,” Biochemical Pharmacology 227 (2024): 116457.

[108] Q. He, J. Pan, Y. Zhang, et al., “Multifunctional Nanobody Fusion Proteins in Immunoassays: Diverse Strategies for Enhanced Analytical Performance,” TrAC, Trends in Analytical Chemistry 192 (2025): 118404.

[109] L. He, Q. Wu, Z. Zhang, et al., “Development of Broad-Spectrum Nanobodies for the Therapy and Diagnosis of SARS-CoV-2 and Its Multiple Variants,” Molecular Pharmaceutics 21, no. 8 (2024): 3866–3879.

[110] Q. Jia, Z. Ma, Y. Wang, et al., “Integrated Single-Step Terahertz Metasensing for Simultaneous Detection Based on Exosomal Membrane Proteins Enables Pathological Typing of Gastric Cancer,” Research 8 (2025): 0625.

[111] R. Wang, L. Song, H. Ruan, et al., “Ultrasensitive Terahertz Label-Free Metasensors Enabled by Quasi-Bound States in the Continuum,” Research 7 (2024): 0483.

[112] M. L. Yang, T. Z. Yuan, K. Y. Chan, et al., “A VHH Single-Domain Platform Enabling Discovery and Development of Monospecific Antibodies and Modular Neutralizing Bispecifics Against SARS-CoV-2 Variants,” Antibody Therapeutics 7, no. 2 (2024): 164–176.

[113] J. Wang, B. Shi, H. Chen, et al., “Engineered Multivalent Nanobodies Efficiently Neutralize SARS-CoV-2 Omicron Subvariants BA. 1, BA. 4/5, XBB. 1 and BQ. 1.1,” Vaccines 12, no. 4 (2024): 417.

[114] J. Huang, Y. Sun, Y. Jiang, et al., “Deep Learning-Assisted Electronic Skin System Capable of Capturing Spatiotemporal and Mechanical Features of Social Touch to Enhance Human–Robot Emotion Recognition,” SmartMat 6, no. 1 (2025): e1325.

[115] Y. Peng, Y. Huang, F. Kiessling, D. Renn, and M. Rueping, “Nanobody-Based Lateral Flow Immunoassay for Rapid Antigen Detection of SARS-CoV-2 and MERS-CoV Proteins,” ACS Synthetic Biology 14, no. 2 (2025): 420–430.

[116] E. Jeong, S. Y. Oh, S. U. Son, et al., “Nanobody Engineering for Enhanced-Sensitivity Rapid COVID-19 Tests,” Nanoscale 17, no. 40 (2025): 23329–23342.

[117] P. J. Halfmann, J. S. Lee, N. McArthur, O. Gupta, Y. Kawaoka, and R. S. Kane, “Potent Bivalent Nanobody Constructs That Protect Against the SARS-CoV-2 XBB Variant,” npj Viruses 3, no. 1 (2025): 19.

[118] Y. Peng, A. Alqatari, F. Kiessling, et al., “Nanobody-Based Lateral Flow Assay for Rapid Zika Virus Detection,” ACS Synthetic Biology 14, no. 3 (2025): 890–900.

[119] J. Wang, Q. Zhou, K. Lowry, C. B. Howard, and M. Trau, “Development and Application of Multivalent Nanobody-Functionalized Plasmonic Probes in SERS Sensing Platforms,” Biosensors and Bioelectronics 278 (2025): 117292.

[120] A. Lizama-Muñoz and J. Plaza-Diaz, “Bispecific Antibodies, Nanobodies and Extracellular Vesicles: Present and Future to Cancer Target Therapy,” Biomolecules 15, no. 5 (2025): 639.

[121] L. Yang, X. Sun, L. Du, et al., “CD205-Targeted Bispecific Nanobody Enhances Antigen Presentation and Immune Responses in FMDV,” Veterinary Vaccine 4, no. 3 (2025): 100131.

[122] M. David, A. Faihy, C. Rolland, et al., “Bispecific Nanobody as a New Pharmacological Drug for the Selective Inhibition of Trypsin-3,” British Journal of Pharmacology 182, no. 19 (2025): 4578–4591.

[123] A. Mohammed and M. I. Muustafa, “Nanobodies: A New Frontier in Antiviral Therapies,” SLAS Discovery 35 (2025): 100251.

[124] J. Wang, Q. Zhou, K. Lowry, C. B. Howard, and M. Trau, “A Digital SERS Platform Powered by Bispecific Antibody Fragments for SARS-CoV-2 Diagnostics,” Biosensors and Bioelectronics 294 (2026): 118252.

[125] M. Mullin, J. McClory, W. Haynes, J. Grace, N. Robertson, and G. van Heeke, “Applications and Challenges in Designing VHH-Based Bispecific Antibodies: Leveraging Machine Learning Solutions,” mAbs 16, no. 1 (2024): 2341443.

[126] T. Li, J. Yang, M. Jiang, et al., “Fusing a Novel Anti-CTLA-4 Nanobody to the IgG1 Fc Region Strengthens Its Ability to Induce CD8⁺ T Cell-Mediated Immune Responses Against Solid Tumors,” International Journal of Nanomedicine 19 (2024): 12311–12321.

[127] P. Ji, K. Wang, L. Zhang, et al., “A New Nanobody-Enzyme Fusion Protein-Linked Immunoassay for Detecting Antibodies Against Influenza a Virus in Different Species,” Journal of Biological Chemistry 298, no. 12 (2022): 102709.

[128] M. Yang, Q. Xu, K. Gu, et al., “Development of a Nanobody-Horseradish Peroxidase Fusion-Based Competitive ELISA to Rapidly and Sensitively Detect Enrofloxacin Residues in Animal-Derived Foods,” Spectrochimica Acta, Part A: Molecular and Biomolecular Spectroscopy 327 (2025): 125309.

[129] M. Sun, Y. Sun, Y. Yang, et al., “Multivalent Nanobody-Based Sandwich Enzyme-Linked Immunosorbent Assay for Sensitive Detection of Porcine Reproductive and Respiratory Syndrome Virus,” International Journal of Biological Macromolecules 258, no. Pt 2 (2024): 128896.

[130] N. Kaushik, P. Patel, R. Gupta, et al., “Eco-Friendly Materials for Next-Generation Vaccination: From Concept to Clinical Reality,” SmartMat 5, no. 5 (2024): e1274.

[131] N. Kiyose, N. Miyazaki, K. Furuhata, and Y. Ito, “Sensitive Immunoassay of Legionella Using Multivalent Conjugates of Engineered VHHs,” Journal of Biochemistry 173, no. 3 (2023): 185–195.

[132] J.-H. Xue, Q.-H. Sun, C. Han, et al., “FeNi Prussian Blue Analogues on Highly Graphitized Carbon Nanosheets as Efficient Glucose Sensors,” Rare Metals 43, no. 6 (2024): 2730–2738.

[133] B. Serruys, F. Van Houtte, A. Farhoudi-Moghadam, G. Leroux-Roels, and P. Vanlandschoot, “Production, Characterization and In Vitro Testing of HBcAg-Specific VHH Intrabodies,” Journal of General Virology 91, no. 3 (2010): 643–652.

[134] N. K. Singh, H. Horo, and V. Rajulapati, “Recent Trends in Clinical Diagnosis for Viral Disease Detection Based on Miniaturized Biosensors.” Miniaturized Biosensing Devices: Fabrication and Applications (Springer, 2022), 123–147.

[135] H.-M. Yang, C.-Y. Tu, Y.-L. Zhuang, et al., “Dual Near-Infrared AgInS₂ and CuInS₂ Co-Sensitized ZnO Photoelectrode Array Enabled Paper-Based Ratiometric Photoelectrochemical Aptasensing,” Rare Metals 43, no. 12 (2024): 6525–6536.

[136] Y. Gu, Y. Guo, Y. Deng, H. Song, R. Nian, and W. Liu, “Development of a Highly Sensitive Immunoassay Based on Pentameric Nanobodies for Carcinoembryonic Antigen Detection,” Analytica Chimica Acta 1279 (2023): 341840.

[137] D. Zheng, Y. Huang, C. Li, et al., “A Radiofluorinated Nanobody PET Tracer to Dynamically Visualize Differential Nectin4 Expression In Vivo,” Journal of Medicinal Chemistry 68, no. 20 (2025): 21366–21376.

[138] K. Zeven, H. Dierick, M. Sevenois, et al., “Optimizing Antibody PET Imaging: A Comparative Preclinical Analysis of Nanobody and Minibody-Like PET Tracers,” European Journal of Nuclear Medicine and Molecular Imaging 52, no. 10 (2025): 3833–3845.

[139] N. N. Alias, A. Masood, P. C. Ooi, et al., “Biosensor Innovations for Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD) Diagnostics,” ACS Applied Bio Materials 8, no. 11 (2025): 9557–9588.

[140] K. S. Park, T.-I. Park, J. E. Lee, S.-Y. Hwang, A. Choi, and S. P. Pack, “Aptamers and Nanobodies as New Bioprobes for SARS-CoV-2 Diagnostic and Therapeutic System Applications,” Biosensors 14, no. 3 (2024): 146.

[141] G. Eshaghi, D. Kaiser, H. R. Rasouli, et al., “Highly Sensitive and Label-Free Detection of SARS-CoV-2 Proteins via Surface Plasmon Resonance Using Biofunctionalization With 1 nm Thick Carbon Nanomembranes,” Scientific Reports 15, no. 1 (2025): 31248.

[142] X. Liu, D. Wang, J. Chu, Y. Xu, and W. Wang, “Sandwich Pair Nanobodies, a Potential Tool for Electrochemical Immunosensing Serum Prostate-Specific Antigen With Preferable Specificity,” Journal of Pharmaceutical and Biomedical Analysis 158 (2018): 361–369.

[143] S. Boonkaew, L. Teodori, M. H. Vendelbo, J. Kjems, and E. E. Ferapontova, “Nanobodies' Duo Facilitates Ultrasensitive Serum HER-2/neu Immunoassays via Enhanced Avidity Interactions,” Analytica Chimica Acta 1335 (2025): 343472.

[144] S. Boonkaew, K. Szot-Karpińska, J. Niedziółka-Jönsson, A. de Marco, and M. Jönsson-Niedziółka, “NFC Smartphone-Based Electrochemical Microfluidic Device Integrated With Nanobody Recognition for C-Reactive Protein,” ACS Sensors 9, no. 6 (2024): 3066–3074.

[145] S. Burgstaller, T. R. Wagner, H. Bischof, et al., “Monitoring Extracellular Ion and Metabolite Dynamics With Recombinant Nanobody-Fused Biosensors,” iScience 25, no. 9 (2022): 104907.

[146] L. Zhou, J. Huang, B. Yu, Y. Liu, and T. You, “A Novel Electrochemiluminescence Immunosensor for the Analysis of HIV-1 p24 Antigen Based on P-RGO@Au@Ru–SiO₂ Composite,” ACS Applied Materials & Interfaces 7, no. 44 (2015): 24438–24445.

[147] D. V. Shcheblyakov, D. V. Voronina, I. A. Favorskaya, et al., “Broadly Reactive Nanobody Targeting the H3 Hemagglutinin of the Influenza a Virus,” Acta Naturae 16, no. 1 (2024): 101–110.

[148] M. A. Kumar, R. Jayavel, S. Mahalingam, J. Kim, and R. Atchudan, “Detection of Interleukin-6 Protein Using Graphene Field-Effect Transistor,” Biosensors 13, no. 9 (2023): 834.

[149] N. Deshpande, P. V. Suryawanshi, and S. Tripathy, “Unveiling the Quest: Crafting an Enzyme-Linked Immunosorbent Assay (ELISA) Technique to Uncover COVID-19 Antibodies,” Cureus 16, no. 8 (2024): e66659.

[150] G. C. Girt, A. Lakshminarayanan, J. Huo, et al., “The Use of Nanobodies in a Sensitive ELISA Test for SARS-CoV-2 Spike 1 Protein,” Royal Society Open Science 8, no. 9 (2021): 211016.

[151] H. Duan, X. Chen, J. Zhao, et al., “Development of a Nanobody-Based Competitive Enzyme-Linked Immunosorbent Assay for Efficiently and Specifically Detecting Antibodies Against Genotype 2 Porcine Reproductive and Respiratory Syndrome Viruses,” Journal of Clinical Microbiology 59, no. 12 (2021): e0158021.

[152] Q. He, M. R. McCoy, M. Qi, et al., “The Generation of a Nanobody-Based ELISA for Human Microsomal Epoxide Hydrolase,” International Journal of Molecular Sciences 24, no. 19 (2023): 14698.

[153] Y. Wang and Y. Xianyu, “Nanobody and Nanozyme-Enabled Immunoassays With Enhanced Specificity and Sensitivity,” Small Methods 6, no. 4 (2022): 2101576.

[154] D. Li, C. Morisseau, C. B. McReynolds, et al., “Development of Improved Double-Nanobody Sandwich ELISAs for Human Soluble Epoxide Hydrolase Detection in Peripheral Blood Mononuclear Cells of Diabetic Patients and the Prefrontal Cortex of Multiple Sclerosis Patients,” Analytical Chemistry 92, no. 10 (2020): 7334–7342.

[155] Y. Hu, Y. Wang, L. Nie, et al., “Exploration of Specific Nanobodies as Immunological Reagents to Detect Milk Allergen of β-lactoglobulin Without Interference of Hydrolytic Peptides,” Journal of Agricultural and Food Chemistry 70, no. 48 (2022): 15271–15282.

[156] L. Yi, H. Liu, Y. Liu, et al., “Nanobody-Based Indirect Competitive ELISA for the Detection of Aflatoxin M1 in Dairy Products,” Scientific Reports 15, no. 1 (2025): 785.

[157] K. Brown, R. S. Blake, and L. Dennany, “Electrochemiluminescence Within Veterinary Science: A Review,” Bioelectrochemistry 146 (2022): 108156.

[158] J. Wang and M. R. Wang, “Comparative Analysis of Electro-Chemiluminescence Immunoassay and Chemiluminescent Microparticle Immunoassay Abilities to Quantitatively Assess Hepatitis B Surface Antigen,” Chinese Journal of Hepatology 21, no. 3 (2013): 192–195.

[159] M. J. Wheeler, “Immunoassay Techniques,” Hormone Assays in Biological Fluids 324 (2006): 1–23.

[160] K. Erler, “Elecsys Immunoassay Systems Using Electrochemiluminescence Detection,” Wiener Klinische Wochenschrift 110 (1998): 5–10.

[161] M. S. Tabatabaei and M. Ahmed, “Enzyme-Linked Immunosorbent Assay (ELISA),” Methods in Molecular Biology 2508 (2022): 115–134.

[162] Y. Li, H. Qi, J. Yang, and C. Zhang, “Detection of DNA Immobilized on Bare Gold Electrodes and Gold Nanoparticle-Modified Electrodes via Electrogenerated Chemiluminescence Using a Ruthenium Complex as a Tag,” Microchimica Acta 164, no. 1 (2009): 69–76.

[163] M. Sornambigai, L. Bouffier, N. Sojic, and S. S. Kumar, “Tris(2,2′-Bipyridyl)Ruthenium (II) Complex as a Universal Reagent for the Fabrication of Heterogeneous Electrochemiluminescence Platforms and Its Recent Analytical Applications,” Analytical and Bioanalytical Chemistry 415, no. 24 (2023): 5875–5898.

[164] H. Li, Y. Sun, J. Elseviers, S. Muyldermans, S. Liu, and Y. Wan, “A Nanobody-Based Electrochemiluminescent Immunosensor for Sensitive Detection of Human Procalcitonin,” Analyst 139, no. 15 (2014): 3718–3721.

[165] H. Wang, G. Li, Y. Zhang, et al., “Nanobody-Based Electrochemical Immunoassay for Ultrasensitive Determination of Apolipoprotein-A1 Using Silver Nanoparticles Loaded Nanohydroxyapatite as Label,” Analytical Chemistry 87, no. 22 (2015): 11209–11214.

[166] Y. He and R. Peng, “Luminol Functionalized Gold Nanoparticles as Colorimetric and Chemiluminescent Probes for Visual, Label Free, Highly Sensitive and Selective Detection of Minocycline,” Nanotechnology 25, no. 45 (2014): 455502.

[167] X.-H. Cao, Q. Wang, J. Li, C. Yi, and M.-J. Li, “Gold Nanoparticles Functionalized With Ru (II) Bipyridyl Labeled DNA as a Luminescent Probe for the Sensitive Determination of DNase I,” Microchimica Acta 184, no. 9 (2017): 3273–3279.

[168] X. Lin, J. Chi, Z. Lian, et al., “One-Droplet Saliva Detection on Photonic Crystal-Based Competitive Immunoassay for Precise Diagnosis of Migraine,” SmartMat 5, no. 5 (2024): e1252.

[169] Q. Lu, X. Li, J. Zhao, et al., “Nanobody‑Horseradish Peroxidase and -EGFP Fusions as Reagents to Detect Porcine Parvovirus in the Immunoassays,” Journal of Nanobiotechnology 18, no. 1 (2020): 7.

[170] H. Liu, Q. Su, S. Duan, et al., “Development of a Nanobody–Alkaline Phosphatase Fusion Protein for Detection of SARS-CoV-2 Spike Protein in a Fluorescence Enzyme Immunoassay,” Analytical Chemistry 96, no. 52 (2024): 20519–20525.

[171] X. Fu, J. Fan, H. Chen, et al., “Nano-Enabled Fluorescence Switching: A Novel Strategy for PDGFRβ Detection and TKI Therapy Monitoring,” Research 9 (2026): 1218.

[172] B. Su, Z. Bei, H. Pei, et al., “Generation of a Nanobody-Alkaline Phosphatase Heptamer Fusion for Ratiometric Fluorescence Immunodetection of Trace Alpha Fetoprotein in Serum,” International Journal of Biological Macromolecules 201 (2022): 507–515.

[173] C. Jia, M. Zhu, Y. He, et al., “Screening for Novel Variable Domains of the Heavy Chains of Heavy-Chain Antibodies Targeting Different Epitopes of Thrombomodulin and Luminex Fluorescence Immunoassay for Soluble Thrombomodulin,” International Journal of Biological Macromolecules 336 (2026): 149289.

[174] W. Hu, Y. Liu, X. Li, et al., “Nanobody-Based Strategy for Rapid and Accurate Pathogen Detection: A Case of COVID-19 Testing,” Biosensors and Bioelectronics 263 (2024): 116598.

[175] J. E. Pinto Torres, J. Goossens, J. Ding, et al., “Development of a Nanobody-Based Lateral Flow Assay to Detect Active Trypanosoma Congolense Infections,” Scientific Reports 8, no. 1 (2018): 9019.

[176] T. A. Bates, S. K. Gurmessa, J. B. Reyes-Weinstein, E. Barklis, and F. G. Tafesse, “A Nanobody-Based Lateral Flow Assay for Point-of-Care Diagnostics,” Biosensors 16, no. 2 (2026): 132.

[177] J. P. Salvador, N. Vasylieva, I. Gonzalez-Garcia, et al., “Nanobody-Based Lateral Flow Immunoassay for the Rapid Detection of Aflatoxin B1 in Almond Milk,” ACS Food Science & Technology 2, no. 8 (2022): 1276–1282.

[178] X. Wang, T. Sun, W. Shen, et al., “A Lateral Flow Immunochromatographic Assay Based on Nanobody-Oriented Coupling Strategy for Aflatoxin B1 Detection,” Sensors and Actuators B: Chemical 394 (2023): 134419.

[179] S. Takahashi, Y. Hiruta, and D. Citterio, “Bioluminescence Readout Lateral Flow Immunoassay Using Nanobody Targeting Aflatoxin B1,” Analyst 150, no. 8 (2025): 1563–1570.

[180] M. Zhang, A. Liu, J. Zhang, et al., “Chemical Engineering of Heterojunction SERS Substrates: Emerging Tools for Disease Diagnosis and Health Monitoring,” SmartMat 6, no. 5 (2025): e70045.

[181] W. Qian, M. Xing, M. Ye, X. Huang, Y. Li, and B. Hao, “Reproducible and Acid-Responsive Rhodamine B/PEG Functioned Nanographene Oxide–Au Nanocomposites for Surface-Enhanced Raman Scattering Sensing,” SmartMat 5, no. 6 (2024): e1305.

[182] X.-Y. Meng, Y.-J. Xie, L. Sun, X.-T. Wang, A.-G. Wu, and J. Lin, “Electromagnetic Field-Charge Transfer Synergy Boosted SERS in Noble Metal-Semiconductor Nanohybrids for Environmental and Bio-Detection,” Rare Metals 44, no. 12 (2025): 9702–9725.

[183] M. Zhang, X. Meng, J. Yu, et al., “A Novel Fe₂O₃@CeO₂ Heterojunction Substrate With High Surface-Enhanced Raman Scattering Performance,” SmartMat 5, no. 6 (2024): e1301.

[184] Y. Yao, Q. Chen, Y.-Q. Li, et al., “Nanodiamond/Ti₃C₂ MXene-Coated Quartz Crystal Microbalance Humidity Sensor With High Sensitivity and High Quality Factor,” Rare Metals 43, no. 6 (2024): 2719–2729.

[185] J. Smolsky, S. Kaur, C. Hayashi, S. Batra, and A. Krasnoslobodtsev, “Surface-Enhanced Raman Scattering-Based Immunoassay Technologies for Detection of Disease Biomarkers,” Biosensors 7, no. 1 (2017): 7.

[186] C. Lin, Y. Li, Y. Peng, et al., “Recent Development of Surface-Enhanced Raman Scattering for Biosensing,” Journal of Nanobiotechnology 21, no. 1 (2023): 149.

[187] A. Kamińska, K. Winkler, A. Kowalska, et al., “SERS-Based Immunoassay in a Microfluidic System for the Multiplexed Recognition of Interleukins From Blood Plasma: Towards Picogram Detection,” Scientific Reports 7, no. 1 (2017): 10656.

[188] J. Sun, W. Li, X. Zhu, et al., “A Novel Multiplex Mycotoxin Surface-Enhanced Raman Spectroscopy Immunoassay Using Functional Gold Nanotags on a Silica Photonic Crystal Microsphere Biochip,” Journal of Agricultural and Food Chemistry 69, no. 38 (2021): 11494–11501.

[189] S. Lee, S. Lee, W. Park, et al., “Plasmonic Annular Nanotrenches With 1 nm Nanogaps for Detection of SARS-CoV-2 Using SERS-Based Immunoassay,” Nano Letters 24, no. 14 (2024): 4233–4240.

[190] M.-N. Li, B. Cao, Y.-L. Wang, et al., “V₂CT_x MXene-Powered Handheld SERS Biosensor for the Viral Antigen Test,” Rare Metals 44, no. 9 (2025): 6442–6455.

[191] J. Wu, H. Liu, W. Chen, B. Ma, and H. Ju, “Device Integration of Electrochemical Biosensors,” Nature Reviews Bioengineering 1, no. 5 (2023): 346–360.

[192] Y. Chen, L. Chen, B. Geng, et al., “Triple-Network-Based Conductive Polymer Hydrogel for Soft and Elastic Bioelectronic Interfaces,” SmartMat 5, no. 3 (2024): e1229.

[193] Y. Li, Y. Ding, J. Sun, et al., “Design Strategies and Emerging Applications of Perovskite-Based Sensors,” SmartMat 6, no. 3 (2025): e70022.

[194] Y. Lei, H. Gao, Z. Qin, et al., “Sensitive and Highly Selective Detection of Organophosphorus Pesticides Using Organic Field-Effect Transistors,” SmartMat 6, no. 2 (2025): e70000.

[195] Y. Zhao and Y. Zhao, “Toward Highly Sensitive, Selective, and Stable Palladium-Based MEMS Gas Sensors for Hydrogen Energy Security,” SmartMat 5, no. 6 (2024): e1303.

[196] M. S. Rahman, E. Helal, and N. R. Demarquette, “Recent Advances in Metal-Organic Framework-Integrated Nanocomposite Hydrogels for Sensors and Sensing Systems,” SmartMat 7, no. 1 (2026): e70061.

[197] J. Wang, Y. Song, X. Dou, et al., “Liquid Crystal Microcavity Biosensors for Real-Time Liver Injury Monitoring via Whispering Gallery Mode Laser,” Research 8 (2025): 0824.

[198] Z.-B. Chen, H.-H. Jin, Z.-G. Yang, and D.-P. He, “Recent Advances on Bioreceptors and Metal Nanomaterials-Based Electrochemical Impedance Spectroscopy Biosensors,” Rare Metals 42, no. 4 (2023): 1098–1117.

[199] S.-J. Zhong, K.-Y. Chen, S.-L. Wang, et al., “Metal-Based Nanowires in Electrical Biosensing,” Rare Metals 43, no. 12 (2024): 6233–6254.

[200] J. Wen, S.-Q. Chen, X. Zhu, et al., “Highly Efficient Non-Enzyme Glucose Sensing by Multi-Component Cuconifesi Alloy With Feather-Like Cu_xO,” Rare Metals 44, no. 9 (2025): 6471–6482.

[201] J. Goode, G. Dillon, and P. A. Millner, “The Development and Optimisation of Nanobody Based Electrochemical Immunosensors for IgG,” Sensors and Actuators B: Chemical 234 (2016): 478–484.

[202] Y.-W. Guo, Q.-H. Wei, F. Wei, et al., “In Situ Synthesis of Porous Pt–Pd Bimetallic Structures for Sweat Glucose Biosensing Using Dynamic Hydrogen Bubble Template Method,” Rare Metals 43, no. 7 (2024): 3408–3414.

[203] L.-L. Li, Y. Zhao, L.-J. Pan, J.-B. Xu, and Y. Shi, “A Direct Electrochemical Biosensor for Rapid Glucose Detection Based on Nitrogen-Doped Carbon Nanocages,” Rare Metals 43, no. 5 (2024): 2184–2192.

[204] S. Trashin, F. Morales-Yánez, S. Thiruvottriyur Shanmugam, et al., “Nanobody-Based Immunosensor Detection Enhanced by Photocatalytic-Electrochemical Redox Cycling,” Analytical Chemistry 93, no. 40 (2021): 13606–13614.

[205] Y. Hu, J. Lin, L. Peng, et al., “Nanobody-Based Electrochemical Immunoassay for Sensitive Detection of Peanut Allergen Ara h 1,” Journal of Agricultural and Food Chemistry 71, no. 19 (2023): 7535–7545.

[206] P. Wen, H. Su, W. Yin, et al., “Fabrication of a High-Sensitivity Electrochemical Immunosensor by the Oriented Immobilization of Engineered Nanobody on Nanofibrous Membrane,” Microchimica Acta 191, no. 11 (2024): 712.

[207] N. Pandey, M. Mandal, D. Samanta, G. Mukherjee, and G. Dutta, “A Nanobody Based Ultrasensitive Electrochemical Biosensor for the Detection of Soluble CTLA-4—A Candidate Biomarker for Cancer Development and Progression,” Biosensors and Bioelectronics 242 (2023): 115733.

[208] H. Wang, M. Qiu, C. Wang, et al., “Light-Triggered Graphene/Black Phosphorus Heterostructure FET Platform for Ultrasensitive Detection of Alzheimer's Disease Biomarkers at the Zeptomole Level,” Research 8 (2025): 0772.

[209] W. Guo, Y. Yu, C. Xin, and G. Jin, “Optical Fiber Immunosensor Based on Nanobody for the Detection of Carcinoembryonic Antigen,” Optical Fiber Technology 84 (2024): 103749.

[210] K. Guo, S. Wustoni, A. Koklu, et al., “Rapid Single-Molecule Detection of COVID-19 and MERS Antigens via Nanobody-Functionalized Organic Electrochemical Transistors,” Nature Biomedical Engineering 5, no. 7 (2021): 666–677.

[211] Z. Zhang, Y. Li, Y. Jing, et al., “Oriented Nanobody-Field-Effect Transistor Interfaces Enable Ultrasensitive Cancer Biomarker Detection,” Nature Sensors 1 (2026): 350–365.

[212] H. Wang, M. Qiu, C. Wang, et al., “Light-Triggered Graphene/Black Phosphorus Heterostructure FET Platform for Ultrasensitive Detection of Alzheimer's Disease Biomarkers at the Zeptomole Level,” Research 8 (2025): 0772.

[213] J. H. E. S. N. Cater, N. S. El Salamouni, G. H. Mansour, et al., “Optimised Nanobody-Based Quenchbodies for Enhanced Protein Detection,” Communications Biology 8, no. 1 (2025): 937.

[214] Z. Dang, S. Ma, B. Sun, et al., “Engineered Multicolor NIR-I/II Fluorescent Proteins for Precise In Vivo Visualization and Imaging-Guided Surgery,” SmartMat 6, no. 5 (2025): e70041.

[215] J. Zhang, K. Tang, Y. Yang, D. Yang, and W. Fan, “Advanced Nanoprobe Strategies for Imaging Macrophage Polarization in Cancer Immunology,” Research 8 (2026): 0622.

[216] F. A. Mann, Z. Lv, J. Großhans, F. Opazo, and S. Kruss, “Nanobody-Conjugated Nanotubes for Targeted Near-Infrared In Vivo Imaging and Sensing,” Angewandte Chemie International Edition 58, no. 33 (2019): 11469–11473.

[217] L. J. Pape, J. Hambach, A. J. Gebhardt, et al., “CD38-specific Nanobodies Allow In Vivo Imaging of Multiple Myeloma Under Daratumumab Therapy,” Frontiers in Immunology 13 (2022): 1010270.

[218] K. Movahedi, S. Schoonooghe, D. Laoui, et al., “Nanobody-Based Targeting of the Macrophage Mannose Receptor for Effective In Vivo Imaging of Tumor-Associated Macrophages,” Cancer Research 72, no. 16 (2012): 4165–4177.

[219] S. Hernot, “Nanobody-Based Fluorescent Contrast Agents for Rapid and Specific Intra-Operative Tumor Visualization,” in Proceedings SPIE PC12825, Molecular-Guided Surgery: Molecules, Devices, and Applications X, PC128250N (March 13, 2024).

[220] W. Zhou, X. Shi, Q. Xu, et al., “Intraoperative Nerve Mapping and Visualization System: Optimal Neurological Function Preservation in Schwannoma Surgery,” SmartMat 6, no. 2 (2025): e70007.

[221] Y. Zhang, Y. Jia, and S. Zhu, “NIR-II Cyanine@Albumin Fluorophore for Deep Tissue Imaging and Imaging-Guided Surgery,” SmartMat 5, no. 4 (2024): e1245.

[222] F. Basuli, J. Shi, E. Lindberg, et al., “Sortase-Mediated Site-Specific Conjugation to Prepare Fluorine-18-Labeled Nanobodies,” Bioconjugate Chemistry 35, no. 9 (2024): 1335–1342.

[223] M. Keyaerts, C. Xavier, J. Heemskerk, et al., “Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma,” Journal of Nuclear Medicine 57, no. 1 (2016): 27–33.

[224] P. Ghosh, L. J. Davies, and C. Nitsche, “Engineered Nanobodies Bind Bismuth, Indium and Gallium for Applications in Theranostics,” Angewandte Chemie 137, no. 5 (2025): e202419455.

[225] X. Guo, C. Li, X. Jia, et al., “NIR-II Fluorescence Imaging-Guided Colorectal Cancer Surgery Targeting CEACAM5 by a Nanobody,” EBioMedicine 89 (2023): 104476.

[226] D. Hu, M. Zha, H. Zheng, D. Gao, and Z. Sheng, “Recent Advances in Indocyanine Green-Based Probes for Second Near-Infrared Fluorescence Imaging and Therapy,” Research 8 (2025): 0583.

[227] C. Xavier, I. Vaneycken, M. D'huyvetter, et al., “Synthesis, Preclinical Validation, Dosimetry, and Toxicity of 68Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer,” Journal of Nuclear Medicine 54, no. 5 (2013): 776–784.

[228] O. Gondry, V. Caveliers, C. Xavier, et al., “Phase II Trial Assessing the Repeatability and Tumor Uptake of [(68)Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients With Breast Carcinoma,” Journal of Nuclear Medicine 65, no. 2 (2024): 178–184.

[229] T. M. Lwin, M. A. Turner, S. Amirfakhri, et al., “Rapid Tumor-Labeling Kinetics With a Site-Specific Near-Infrared Anti-CEA Nanobody in a Patient-Derived Orthotopic Xenograft Mouse Model of Colon Cancer,” Journal of Surgical Oncology 124, no. 7 (2021): 1121–1127.

[230] F. Ramos-Gomes, J. Bode, A. Sukhanova, et al., “Single-and Two-Photon Imaging of Human Micrometastases and Disseminated Tumour Cells With Conjugates of Nanobodies and Quantum Dots,” Scientific Reports 8, no. 1 (2018): 4595.

[231] T. J. Harmand, A. Islam, N. Pishesha, and H. L. Ploegh, “Nanobodies as In Vivo, Non-Invasive, Imaging Agents,” RSC Chemical Biology 2, no. 3 (2021): 685–701.

[232] X. Liu, L. Luan, X. Liu, et al., “A Novel Nanobody-Based HER2-Targeting Antibody Exhibits Potent Synergistic Antitumor Efficacy in Trastuzumab-Resistant Cancer Cells,” Frontiers in Immunology 14 (2023): 1292839.

[233] T. Elverdi and A. E. Eskazan, “Caplacizumab as an Emerging Treatment Option for Acquired Thrombotic Thrombocytopenic Purpura,” Drug Design, Development and Therapy 13 (2019): 1251–1258.

[234] N. Biesemann, D. Margerie, C. Asbrand, et al., “Additive Efficacy of a Bispecific Anti-TNF/IL-6 Nanobody Compound in Translational Models of Rheumatoid Arthritis,” Science Translational Medicine 15, no. 681 (2023): eabq4419.

[235] L. Zhang, M. Zhou, C. Lu, et al., “A High-Affinity CEA-Targeted Nanobody for (68)Ga PET Imaging and (177)Lu-Based Radioisotope Therapy: Preclinical and First-In-Human Evaluation,” Journal of Nanobiotechnology 23, no. 1 (2025): 734.

[236] L. Huang, R. Wang, K. Xie, et al., “A HER2 Target Antibody Drug Conjugate Combined With Anti-PD-(L) 1 Treatment Eliminates hHER2+ Tumors in hPD-1 Transgenic Mouse Model and Contributes Immune Memory Formation,” Breast Cancer Research and Treatment 191, no. 1 (2022): 51–61.

[237] C. Linde, Y.-T. Chien, Z. Chen, and Q. Mu, “Nanoparticle-Enhanced PD-1/PD-L1 Targeted Combination Therapy for Triple Negative Breast Cancer,” Frontiers in Oncology 14 (2024): 1393492.

[238] L. Zhao, J. Gong, S. Liao, W. Huang, J. Zhao, and Y. Xing, “Preclinical Evaluation and Preliminary Clinical Study of 68Ga-NODAGA-NM-01 for PET Imaging of PD-L1 Expression,” Cancer Imaging 25, no. 1 (2025): 6.

[239] M. Scully, S. R. Cataland, F. Peyvandi, et al., “Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura,” New England Journal of Medicine 380, no. 4 (2019): 335–346.

[240] F. Peyvandi, M. Scully, J. A. Kremer Hovinga, et al., “Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura,” New England Journal of Medicine 374, no. 6 (2016): 511–522.

[241] F. Peyvandi, S. Cataland, M. Scully, et al., “Caplacizumab Prevents Refractoriness and Mortality in Acquired Thrombotic Thrombocytopenic Purpura: Integrated Analysis,” Blood Advances 5, no. 8 (2021): 2137–2141.

[242] Y. Tanaka “Ozoralizumab: First Nanobody Therapeutic for Rheumatoid Arthritis,” Expert Opinion on Biological Therapy 23, no. 7 (2023): 579–587.

[243] Y. Tanaka, M. Kawanishi, M. Nakanishi, H. Yamasaki, and T. Takeuchi, “Efficacy and Safety of the Anti-TNF Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: A 52-week Result of a Phase II/III Study (OHZORA Trial),” Modern Rheumatology 33, no. 5 (2023): 883–890.

[244] J. Li, Y. Deng, W. Zhang, et al., “Subcutaneous Envafolimab Monotherapy in Patients With Advanced Defective Mismatch Repair/Microsatellite Instability High Solid Tumors,” Journal of Hematology & Oncology 14, no. 1 (2021): 95.

[245] K. P. Papadopoulos, W. Harb, C. J. Peer, et al., “First-In-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients With Advanced Solid Tumors,” Oncologist 26, no. 9 (2021): e1514–e1525.

[246] J. G. Berdeja, D. Madduri, S. Z. Usmani, et al., “Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1): A Phase 1b/2 Open-Label Study,” Lancet 398, no. 10297 (2021): 314–324.

[247] K. A. Papp, M. A. Weinberg, A. Morris, and K. Reich, “IL17A/F Nanobody Sonelokimab in Patients With Plaque Psoriasis: A Multicentre, Randomised, Placebo-Controlled, Phase 2b Study,” Lancet 397, no. 10284 (2021): 1564–1575.

[248] R. S. Salieva, “Nanobody Therapeutics in Autoimmune and Immune-Mediated Inflammatory Diseases: Experimental Insights and Translational Strategies,” International Immunopharmacology 166 (2025): 115552.

[249] K. Vijayandran, A. I. K. Abdo, M. T. J. Wong, et al., “Nanobodies Targeting Cytokines for the Amelioration of Autoimmune Diseases,” International Immunopharmacology 164 (2025): 115368.

[250] Q. Yao, F. Zhang, Z. Yang, Y. Sun, and W. Gao, “A Super-Long-Acting Anti-PD-L1 Nanobody Fused to Elastin-Like Polypeptide for Triple-Negative Breast Cancer Immunotherapy,” Journal of Controlled Release 385 (2025): 114002.

[251] M. Blueggel, D. Gül, R. H. Stauber, and S. K. Knauer, “Small But Mighty: The Versatility of Nanobodies in Modern Medicine,” Nanoscale Horizons 10, no. 10 (2025): 2158–2171.

[252] B. Natarajan, P. Kannan, P. Subramanian, and G. Maduraiveeran, “Metal Nanoparticles Based Electrochemical Biosensing of Neutrophil Gelatinase-Associated Lipocalin Biomarker for Monitoring Acute Kidney Injury,” Microchemical Journal 203 (2024): 110890.

[253] K. Gu, Z. Song, C. Zhou, et al., “Development of Nanobody-Horseradish Peroxidase-Based Sandwich Elisa to Detect Salmonella Enteritidis in Milk and In Vivo Colonization in Chicken,” Journal of Nanobiotechnology 20, no. 1 (2022): 167.

[254] Y. Xing, G. Chand, C. Liu, et al., “Early Phase I Study of a 99mTc-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer,” Journal of Nuclear Medicine 60, no. 9 (2019): 1213–1220.

[255] T. Li, S. Qi, M. Unger, et al., “Immuno-Targeting the Multifunctional CD38 Using Nanobody,” Scientific Reports 6 (2016): 27055.

[256] G. Crișan, N. S. Moldovean-Cioroianu, D.-G. Timaru, G. Andrieș, C. Căinap, and V. Chiș, “Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review Over the Last Decade,” International Journal of Molecular Sciences 23, no. 9 (2022): 5023.

[257] L. Li, X. Lin, L. Wang, et al., “Immuno-PET of Colorectal Cancer With a CEA-Targeted [68 Ga] Ga-Nanobody: From Bench to Bedside,” European Journal of Nuclear Medicine and Molecular Imaging 50, no. 12 (2023): 3735–3749.

[258] Z. Miao, G. Ren, H. Liu, S. Qi, S. Wu, and Z. Cheng, “PET of EGFR Expression With an 18F-Labeled Affibody Molecule,” Journal of Nuclear Medicine 53, no. 7 (2012): 1110–1118.

[259] A. Blykers, S. Schoonooghe, C. Xavier, et al., “PET Imaging of Macrophage Mannose Receptor–Expressing Macrophages in Tumor Stroma Using 18F-Radiolabeled Camelid Single-Domain Antibody Fragments,” Journal of Nuclear Medicine 56, no. 8 (2015): 1265–1271.

[260] J. Han, Y. Chen, Y. Zhao, et al., “Pre-Clinical Study of the [18F]AlF-Labeled HER2 Affibody for Non-Invasive HER2 Detection in Gastric Cancer,” Frontiers in Medicine 9 (2022): 803005.

[261] M. Kijanka, F. J. Warnders, M. El Khattabi, et al., “Rapid Optical Imaging of Human Breast Tumour Xenografts Using Anti-HER2 VHHs Site-Directly Conjugated to IRDye 800CW for Image-Guided Surgery,” European Journal of Nuclear Medicine and Molecular Imaging 40, no. 11 (2013): 1718–1729.

[262] M. D'Huyvetter, J. D. Vos, V. Caveliers, et al., “Phase I Trial of (131) I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients,” Journal of Nuclear Medicine 62, no. 8 (2021): 1097–1105.

[263] Y. Liu, J. Liu, Z. Qiu, et al., “Advancements in Nanobody-Based Immunodiagnostics and Infectious Pathogens, Foodborne Hazards, and Human Biomarkers,” Microchemical Journal 214 (2025): 114083.

[264] E. Yang, Q. Liu, G. Huang, J. Liu, and W. Wei, “Engineering Nanobodies for Next-Generation Molecular Imaging,” Drug Discovery Today 27, no. 6 (2022): 1622–1638.

[265] Y. Yuan, C. Zhuoga, C. Zeng, et al., “Advances in Nanobody-Based Platforms for Precision Cancer Diagnosis and Therapy,” Polymer Science & Technology 1, no. 8 (2025): 692–715.

[266] Y.-C. Ouyang, B.-J. Yeom, Y. Zhao, and W. Ma, “Progress and Prospects of Chiral Nanomaterials for Biosensing Platforms,” Rare Metals 43, no. 6 (2024): 2469–2497.

[267] X.-H. Zhang, B. Wang, B. Zhou, et al., “Recent Advances in MXene-Based Flexible Pressure Sensors for Medical Monitoring,” Rare Metals 44, no. 6 (2025): 3653–3685.

[268] T. N. L. Phan, T. X. Nguyen, T. T. Truong, et al., “Advancements, Challenges, and Future Perspectives of MXenes in Biomedicine,” SmartMat 6, no. 2 (2025): e70009.

[269] C. Ackaert, N. Smiejkowska, C. Xavier, et al., “Immunogenicity Risk Profile of Nanobodies,” Frontiers in Immunology 12 (2021): 632687.

[270] B. Van Butsel, M. L. Sargentini-Maier, A. P. Marques, et al., “Complex Immunogenicity Assessment in Caplacizumab-Treated Patients With Immune-Mediated Thrombotic Thrombocytopenic Purpura Who Have Received Plasma Exchange,” Research and Practice in Thrombosis and Haemostasis 8, no. 8 (2024): 102620.

[271] I. B. McInnes, L. C. Coates, P. J. Mease, et al., “Sonelokimab, an IL-17A/IL-17F-inhibiting Nanobody for Active Psoriatic Arthritis: A Randomized, Placebo-Controlled Phase 2 Trial,” Nature Medicine 31, no. 12 (2025): 4160–4171.

[272] Y. Ding, J. Chen, Q. Wu, et al., “Artificial Intelligence-Assisted Point-of-Care Testing System for Ultrafast and Quantitative Detection of Drug-Resistant Bacteria,” SmartMat 5, no. 3 (2024): e1214.

[273] W. Song, W. Wei, X. Lan, and W. Cai, “Albumin Binding Improves Nanobody Pharmacokinetics for Dual-Modality PET/NIRF Imaging of CEACAM5 in Colorectal Cancer Models,” European Journal of Nuclear Medicine and Molecular Imaging 50, no. 9 (2023): 2591–2594.

[274] W. Wei, M. H. Younis, X. Lan, J. Liu, and W. Cai, “Single-Domain Antibody Theranostics on the Horizon,” Journal of Nuclear Medicine 63, no. 10 (2022): 1475–1479.

[275] Y. Mo, J. Wang, H. Yang, L. Bai, K. Xu, and J. Su, “Artificial Intelligence for Organoids Multidimensional Assessment,” SmartMat 6, no. 3 (2025): e70016.

[276] P. Shrestha, C. S. Talwar, J. Kandel, et al., “Nanobinder: A Machine Learning Assisted Nanobody Binding Prediction Tool Using Rosetta Energy Scores,” Journal of Cheminformatics 17, no. 1 (2025): 96.

[277] J. E. Shin, A. J. Riesselman, A. W. Kollasch, et al., “Protein Design and Variant Prediction Using Autoregressive Generative Models,” Nature Communications 12, no. 1 (2021): 2403.

[278] K. Swanson, W. Wu, N. Bulaong, J. Pak, and J. Zou, “The Virtual Lab of AI Agents Designs New SARS-CoV-2 Nanobodies,” Computational and Structural Biotechnology Journal 27 (2025): 3443–3455.

[279] A. Ramon, M. Ali, M. Atkinson, et al., “Assessing Antibody and Nanobody Nativeness for Hit Selection and Humanization With AbNatiV,” Nature Machine Intelligence 6, no. 1 (2024): 74–91.

[280] Z. Sang, Y. Xiang, I. Bahar, and Y. Shi, “Llamanade: An Open-Source Computational Pipeline for Robust Nanobody Humanization,” Structure 30, no. 3 (2022): 418–429.e3.

[281] L. Huo, T. Tian, Y. Xu, Q. Qin, X. Jiang, and Q. Huang, “Computational Nanobody Design Through Deep Generative Modeling and Epitope Landscape Profiling,” Computational and Structural Biotechnology Journal 27 (2025): 3443–3455.

[282] F. Mo, S. Duan, X. Jiang, et al., “Nanobody-Based Chimeric Antigen Receptor T Cells Designed by CRISPR/Cas9 Technology for Solid Tumor Immunotherapy,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 80.

[283] J. Boylan, R. A. Shrem, I. C. Vallecillo-Viejo, C. L. Duvall, B. E. Wadzinski, and B. W. Spiller, “A Nanobody Toolbox for Recognizing Distinct Epitopes on Cas9,” Journal of Molecular Biology 436, no. 23 (2024): 168836.

[284] D. M. Mason, C. R. Weber, C. Parola, et al., “High-Throughput Antibody Engineering in Mammalian Cells by CRISPR/Cas9-Mediated Homology-Directed Mutagenesis,” Nucleic Acids Research 46, no. 14 (2018): 7436–7449.

[285] C. Parola, D. Neumeier, S. Friedensohn, et al., “Antibody Discovery and Engineering by Enhanced CRISPR-Cas9 Integration of Variable Gene Cassette Libraries in Mammalian Cells,” mAbs 11, no. 8 (2019): 1367–1380.

[286] M. Al-Seragi, Y. Chen, and F. Duong van Hoa, “Advances in Nanobody Multimerization and Multispecificity: From In Vivo Assembly to In Vitro Production,” Biochemical Society Transactions 53, no. 1 (2025): 235–248.

[287] S. Peshin, A. Gavin, N. Rie, et al., “Interplay of the Mass Transport and Reaction Kinetics for Lateral Flow Immunoassay Integrated on Lab-on-Disc,” Sensors 25, no. 20 (2025): 6271.

[288] J. Yu, D. Stankovic, J. Vidic, and N. Sojic, “Recent Advances in Electrochemiluminescence Immunosensing,” Sensors & Diagnostics 3, no. 12 (2024): 1887–1898.

[289] Y. Zhang, Y. Huang, R. Li, et al., “Site-Specific Labeling of Antibodies With Quantum Dots Could Promote to Retain the Antigen Binding Capacity of Antibodies,” Food Chemistry 413 (2023): 135655.

[290] A. Isaacs, A. A. Amarilla, J. Aguado, et al., “Nucleocapsid Specific Diagnostics for the Detection of Divergent SARS-CoV-2 Variants,” Frontiers in Immunology 13 (2022): 926262.

[291] H. Zhao, C. Wang, Y. Yang, et al., “ImmunoPET Imaging of Human CD8(+) T Cells With Novel (68)Ga-Labeled Nanobody Companion Diagnostic Agents,” Journal of Nanobiotechnology 19, no. 1 (2021): 42.

[292] R. Sánchez-Salcedo, R. Miranda-Castro, N. de-Los-Santos-Álvarez, M. J. Lobo-Castañón, and D. K. Corrigan, “Comparing Nanobody and Aptamer-Based Capacitive Sensing for Detection of interleukin-6 (IL-6) at Physiologically Relevant Levels,” Analytical and Bioanalytical Chemistry 415, no. 29–30 (2023): 7035–7045.

[293] C. S. Talwar, J. H. Choi, S. I. Nurheibah, et al., “Development of a High-Sensitivity Interleukin-6 Biosensor by Combining Nanobody Engineering and Solution-Immersed Silicon Ellipsometry,” Chemical Engineering Journal 525 (2025): 170017.

[294] C. Gerdes, N. Waal, T. Offner, et al., “A Nanobody-Based Fluorescent Reporter Reveals Human α-Synuclein in the Cell Cytosol,” Nature Communications 11, no. 1 (2020): 2729.

[295] S. R. Meier, D. Sehlin, and S. Syvänen, “Passive and Receptor Mediated Brain Delivery of an Anti-GFAP Nanobody,” Nuclear Medicine and Biology 114–115 (2022): 128–134.

[296] T. Morito, R. Harada, R. Iwata, et al., “Evaluation of 18F Labeled Glial Fibrillary Acidic Protein Binding Nanobody and Its Brain Shuttle Peptide Fusion Proteins Using a Neuroinflammation Rat Model,” PLoS One 18, no. 6 (2023): e0287047.

[297] F. Zheng, Y. Pang, L. Li, et al., “Applications of Nanobodies in Brain Diseases,” Frontiers in Immunology 13 (2022): 978513.

RIGHTS & PERMISSIONS

2026 The Author(s). SmartMat published by Tianjin University and John Wiley & Sons Australia, Ltd.